4//SEC Filing
O'Connell Joseph P 4
Accession 0001209191-21-000935
CIK 0001717452other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:04 PM ET
Size
7.7 KB
Accession
0001209191-21-000935
Insider Transaction Report
Form 4
O'Connell Joseph P
Chief Medical Officer
Transactions
- Award
Common Stock
2020-12-31$16.32/sh+169$2,758→ 3,169 total - Award
Employee Stock Option (Right to Buy)
2020-12-31+169→ 169 totalExercise: $19.20Exp: 2030-12-31→ Common Stock (169 underlying)
Footnotes (2)
- [F1]These shares were acquired on 12/31/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.
Documents
Issuer
Odonate Therapeutics, Inc.
CIK 0001717452
Entity typeother
Related Parties
1- filerCIK 0001723966
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 4:04 PM ET
- Size
- 7.7 KB